Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma by Lenzi, Renato et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
Journal of Translational Medicine
Open Access Research
Phase II study of intraperitoneal recombinant interleukin-12 
(rhIL-12) in patients with peritoneal carcinomatosis (residual 
disease < 1 cm) associated with ovarian cancer or primary 
peritoneal carcinoma
Renato Lenzi*1, Robert Edwards2, Carl June3, Michael V Seiden4, 
Michael E Garcia5, Michael Rosenblum6 and Ralph S Freedman5
Address: 1Department of GI Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA, 2Department of 
Obstetrics & Gynecology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA, 3Abramson Cancer Center, University of Pennsylvania, 
Philadelphia, PA, USA, 4Fox Chase Cancer Center, Philadelphia, PA, USA, 5Department of Gynecologic Oncology, The University of Texas M.D. 
Anderson Cancer Center, Houston, Texas, USA and 6Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer 
Center, Houston, Texas, USA
Email: Renato Lenzi* - rlenzi@mdanderson.org; Robert Edwards - redwards@mail.magee.edu; Carl June - cjune@mail.med.upenn.edu; 
Michael V Seiden - michael.seiden@fccc.edu; Michael E Garcia - mgarcia@mdanderson.org; Michael Rosenblum - mrosenbl@mdanderson.org; 
Ralph S Freedman - rfreedma@mdanderson.org
* Corresponding author    
Abstract
Background: Pharmacokinetic advantages of intraperitoneal (IP) rhIL-12, tumor response to IP
delivery of other cytokines as well as its potential anti-angiogenic effect provided the rationale for
further evaluation of IPrhIL-12 in patients with persistent ovarian or peritoneal carcinoma.
Methods: A phase 2 multi-institutional trial (NCI Study #2251) of IP rIL-12 (300 nanogram/Kg
weekly) was conducted in patients with ovarian carcinoma or primary peritoneal carcinoma.
Patients treated with primary therapy for ovarian cancer who had no extraabdominal/parenchymal
disease or bulky peritoneal disease were eligible. Four to 8 weeks from last chemotherapy, eligible
patients underwent a laparotomy/laparoscopy. Patients with residual disease ≤ 1 cm were
registered for the treatment phase 2–5 weeks post surgery. The effect of IP rIL-12 on the
expression of TNFα , INFα , IL-10, IP-10, IL-8, FGF, VEGF was also studied.
Results: Thirty-four patients were registered for the first screening phase of the study. Median age
was 56.6 years (range: 31–71); 12 completed the second phase and were evaluable for response/
toxicity. Performance scores of IL-12 treated patients were 0 (11 pts) and 1 (1 pt). There were no
treatment related deaths, peritonitis or significant catheter related complications. Toxicities
included grade 4 neutropenia (1), grade 3 fatigue (4), headache (2), myalgia (2), non-neutropenic
fever (1), drug fever (1), back pain (1), and dizziness (1). The best response observed was SD. Two
patients had SD and 9 had PD, and 1 was evaluable for toxicity only.
Peritoneal fluid cytokine measurements demonstrated a ≥ 3 fold relative increase post-rhIL-12:
IFN-γ, 5/5 pts; TNF-α , 1/5; IL-10, 4/5; IL-8, 5/5; and VEGF, 3/5. IP10 levels were increased in 5/5
patients. Cytokine response profiles suggest either NK or T-cell mediated effects of IP rhIL-12.
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Cytokine/chemokine results also suggest a pleiotropic response since proteins with potential for
either anti-tumor (IFN-γ , IP-10) or pro-tumor growth effects (VEGF, IL-8) were detected.
Conclusion: IP IL-12 can safely be administered at this dose and schedule to patients after first
line chemotherapy for ovarian/peritoneal carcinoma. The maximum response was stable disease.
Future IP therapies with rhIL-12 will require better understanding and control of pleiotropic effects
of IL-12.
Introduction
The limited success of systemic chemotherapy for the
treatment of Mullerian type carcinomas involving the per-
itoneum has promoted interest in the intraperitoneal (IP)
route of administration of therapeutic agents for this con-
dition. Advantages of IP administration of biologics
include a lower clearance rate relative to plasma, and
higher concentration in IP fluids relative to plasma, pro-
ducing a possible direct effect on the tumor [1]. Patholog-
ical responses have been observed following
intraperitoneally administered rIFN-α [2,3], rIFN-γ [4],
and rIL-2 [5,6]. IL-12 a large heterodimer, is a powerful
inducer of the production of IFN-γ and TNF-α, cytotoxic
natural killer and T-lymphocytes and of lymphokine-acti-
vated killer cells. Additionally, IL-12 has anti-angiogenic
activity in animal studies [7,8].
In a Phase I study [9] of IP IL-12 in patients with perito-
neal carcinomatosis from Mullerian and gastrointestinal
primary tumors who were not responding to standard
chemotherapy treatment, rhIL-12 was given weekly on 4
week cycles. Patients were evaluated for response every
two cycles. Patients with stable disease or responding were
treated for up to 6 months. Dose levels ranged from 3 to
600 ng/kg. Of the 26 patients entered in the phase1 study,
none were removed because of dose-limiting toxicities.
The only grade 4 toxicities were 2 instances of grade 4 lym-
phopenia. DLT was reached at 600 ng/kg. DLT was indi-
cated by elevation of transaminases that did not return to
baseline by the scheduled start of next treatment cycle. In
that study one patient experienced a CR laparoscopically
documented and 7 patients had stable disease. Based on
these results the dose of 300 ng/kg administered weekly
was selected for the phase 2 study. The previous study also
included detailed pharmacokinetics and pharmacody-
namics [9].
Methods
This phase 2 multi-institutional clinical trial of intraperi-
toneal recombinant interleukin-12 (Genetics Institute,
Cambridge, MA, U.S.A.)  in patients with epithelial ovar-
ian carcinoma or primary peritoneal carcinoma with
residual disease less than 1 cm in maximum diameter after
cancer reductive surgery and platinum based chemother-
apy had the primary goals to assess response rate by a
laparoscopy or laparotomy, to determine the qualitative
and quantitative toxicity of interleukin 12, and to measure
progression-free survival.
Secondary objectives included the measurement of
changes in posttreatment cytokine profiles, the effect of
intraperitoneal interleukin-12 on the expression of VEGF,
FGF2, and IL-8 as surrogate markers of angiogenesis. The
study was approved by the IRBs at University of Texas
M.D. Anderson Cancer Center, Massachusetts General
Hospital, University of Louisville and University of Penn-
sylvania.
Eligibility criteria included a pathologic diagnosis of peri-
toneal carcinomatosis secondary to ovarian or primary
peritoneal tumors, surgically documented peritoneal dis-
ease of < 1 cm after primary treatment including surgery
and platinum based chemotherapy, adequate bone mar-
row, liver, renal function, successful placement of IP cath-
eter, Zubrod performance status of ≤ 1.
Exclusion criteria included intra-abdominal disease of ≥ 1
cm in max diameter, any extra-abdominal or parenchymal
disease, and conditions with the potential to negatively
affect immunocompetence (such as chronic use of ster-
oids, HIV, hepatitis B or C).
The study plan included the initial enrollment of patients
who had received primary therapy for their cancer and
who had no evidence of extraabdominal/parenchymal
disease or of peritoneal disease ≥ 1 cm in max diameter by
imaging studies (CT or MRI). After 4–8 weeks from last
chemotherapy the patients underwent a laparotomy/
laparoscopy. Patients with residual disease meeting the
above criteria were then registered a second time for the
treatment phase of the study 2–5 weeks after the laparot-
omy/laparoscopy. The study was originally powered to
show a greater than 20% response rate with 30 patients.
Peritoneal fluid samples were stored at -20°C and meas-
ured for IL-12p70, INF-γ, TNF-α, IL-8, VEGF and IL-10
using the Luminex Multiplex assay and ELISA at M. D.
Anderson's Human Cancer Immunology Research Facility
using methods previously described [10]. Briefly, the mul-
tiplex bead immunoassay is a multiplex assay designed to
work with the Luminex 100 analyzer (Luminex, Austin,
TX), associated software, and fluorescently encodedJournal of Translational Medicine 2007, 5:66 http://www.translational-medicine.com/content/5/1/66
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microspheres. The minimum detectable levels of each
cytokine with this method were (pg/ml): TNF-α, 8.5 ng/
ml; IL12p70, 3.5 ng/ml; INFγ, 0.8 ng/ml; VEGF, 24.6 ng/
ml; IL10, 1.9 ng/ml; IL8, 1.6 ng/ml; and IP10, 3.2 ng/ml.
Results
Thirty-four patients were registered for the first phase of
the study. Of those, one subsequently declined the proce-
dure. Fourteen had a negative second look laparoscopy.
Nineteen patients had a positive second look procedure.
Of those, 3 had residual disease of > 1 cm and were not
eligible for the second phase of the study. In two, a perito-
neal catheter could not be placed and 14 were registered
for the second phase. Of those 14 patients, 2 were subse-
quently determined to be ineligible because of an inade-
quate blood count or because of a treatment-free interval
that exceeded the permitted range. Demographics
included: 31 white, 2 black, and 1 Asian; the median age
was 56.6 years (range: 31–71).
Of the 12 evaluable patients, 11 were evaluable for
response and toxicity; one was evaluable for toxicity only
because she was treated for only one month. PS was
Zubrod 0 (11 pts) and 1 (1 pt).
Pathological tumor types of evaluable patients included:
serous carcinoma (11 pts) and adenocarcinoma (1 pt).
Response and survival
The best response observed was SD. Two patients had SD
and 9 had PD. One patient who was not adequately
treated for response evaluation developed neutropenia
after 1 week of treatment that did not resolve in time for
further dosing. Due to the above response rate (0/12), the
protocol was closed to accrual. Of the 14 treated patients,
10 are currently alive and 4 have expired. Five of the
patients had a third look laparotomy, the remainder had
PD by radiological criteria (CT) and were therefore not eli-
gible for third look. At 16+/-2 weeks, 1 of 5 pts had no
change, 4 had PD. One patient with no change by CT
declined third look laparotomy, 1 pt had PD in one iso-
lated diaphragmatic focus that was subsequently treated
with Doxil for 18 cycles and eventually surgically com-
pletely resected. A CT at 3 years demonstrated progression
at multiple sites.
Number of courses
Thirty-eight courses of therapy were administered to 12
patients (4 weeks = 1 course, 1 IL-12 IP injection/week).
These represented a mean and range of 10.75 (1–16)
weeks of treatment.
Toxicity
There were no treatment related deaths. There were no
episodes of peritonitis or other catheter-related complica-
tions. Grade 4 toxicities were represented by 1 instance of
grade 4 neutropenia requiring removal from study, and
grade 3 toxicities of fatigue (4), headache (2), myalgia (2),
non-neutropenic fever (1), drug fever (1), back pain (1),
dizziness (1).
Peritoneal fluid cytokine levels
Serial multiplex ELISA assays for IL-12p70, IFN-γ, TNF-α,
IL-10, IL-8, VEGF, and IP-10, were performed on perito-
neal fluid samples obtained from 5 patients following the
first injection of IP rhIL-12 (Table 1). Pretreatment IL-
12p70 values were close to the limit of detection in 5 of 5
patients (8.5, range 6.1–8.7). Peak levels of IL-12p70 were
detected at 6 hours and then slowly declined to 48 hours.
Greater than 3-fold elevation in the levels of the following
cytokines/chemokines were detected post-treatment: IFN-
γ, 5/5; TNF-α, 1/5; IL-10, 4/5; VEGF, 3/5; IL-8, 5/5; and IP-
10, 5/5.
Discussion
Protocol feasibility was less than anticipated, as only 12 of
34 patients who underwent second look laparotomy/
laparoscopy were eligible for treatment having residual
disease  ≤ 1 cm in maximum linear diameter. A larger
number of patients had to be screened surgically to deter-
mine eligibility for the second registration since many
were negative for tumor, had tumors too large for the
treatment, or adhesions precluded adequate treatment.
These factors cannot be determined accurately utilizing
non-surgical approaches. It is also possible that accrual to
the study was adversely affected by competing first line
studies for ovarian cancer that disallow surgical re-evalua-
tion and because it has become accepted practice that sec-
ond look does not afford a survival benefit. Our data
emphasize the pressing clinical need for novel non-inva-
sive radiologic modalities to identify small residual dis-
ease which is optimal for IP therapy. CA125 has
performed well as a surrogate for radiological studies [11],
but has not been adequately evaluated and validated as a
marker for disease progression or response while patients
are receiving IP therapy. The catheter and/or endogenous
cytokines produced in response to treatment might pro-
duce inflammatory effects of treatment that affect sys-
temic CA125 levels.
The study was originally powered to show a greater than
20% response rate with 30 patients. Accrual to the therapy
phase was stopped early. However, the results from this
study failed to show significant benefit from IP rIL12 at
this dose and schedule in any of 11 patients evaluable for
response. Ten of 12 treated patients reached the 8 weeks'
treatment timeline for reevaluation with no objective
responses observed. Only one surgically validated SD was
observed out of 5 patients who underwent third look
laparotomy/laparoscopy. Cytokine responses indicatedJournal of Translational Medicine 2007, 5:66 http://www.translational-medicine.com/content/5/1/66
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either NK or T-cell mediated effects of IP rhIL-12 with
results suggesting pleiotropism with endogenous produc-
tion of immunostimulatory cytokines or chemokines
(IFN-γ, IP-10) or tumor-promoting effects (VEGF and IL-
8). Elevated levels of IL-10 could be the result of stimula-
tion of either macrophages [12] or certain T-cell subsets
such as T-regs although TNF-α levels were only increased
in 1 of 5 patients. Insufficient cellular material was avail-
able to examine cellular responses. We have, however, in
a separate study, shown that tryptophan levels may
decrease after IP IL12 and that nitrate levels may increase
[13]. This raises a concern since the endogenous produc-
tion of nitric oxide can be damaging to either tumor cells
or immune effector cells.  There is also the possibility that
local production of IFN-γ might shift the arginine path-
way toward polyamine production which can have a stim-
ulatory effect on tumor metabolism [14].
Conclusion
rhIL-12 can be safely administered IP to patients with
ovarian or primary peritoneal disease and abdominal car-
cinomatosis.
The true rate of response is difficult to estimate based on
the data obtained from this study since the projected
accrual was not reached. Since there were 0/12 responses
in evaluable patients, the RR would be unlikely to exceed
20% or be strongly supportive of future studies with IP
rhIL12. Furthermore, pleiotropic effects of rhIL-12 on dif-
ferent target cell populations could produce mixed pro-
and anti-tumor growth effects, suggesting that the use of
rhIL-12 may have a limited role in the treatment of ovar-
ian cancer in this setting.
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